The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders ...

Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline AchievementsRaanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ...

Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report ...

Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an ...

Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal ...

The MarketWatch News Department was not involved in the creation of this content. Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a ...

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production ...

Collaboration aims to leverage Polyrizon’s advanced proprietary intranasal delivery platform to support clinical development of Clearmind’s drug candidate proprietary MEAI Raanana, Israel, Feb. 06, ...

Shares of Polyrizon Ltd (NASDAQ:PLRZ) surged 223% to 82 cents Friday afternoon, following a reversal in reverse stock split plans from Thursday. What To Know: On Thursday morning, the company had ...

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted ...

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted ...

Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions ...